Cetera Investment Advisers Grows Holdings in Liquidia Technologies, Inc. (NASDAQ:LQDA)

Key Points

• Cetera Investment Advisers increased its stake in Liquidia Technologies by 34.4%, owning 41,999 shares valued at $619,000 as per the recent SEC filing.
• Insider trading activity included CFO Michael Kaseta selling 30,000 shares worth $600,000, along with other insiders reportedly selling nearly 90,277 shares recently.
• Analysts have set various price targets for Liquidia Technologies, with Wells Fargo raising its target to $31.00 and Raymond James increasing it to $41.00, while the average price target is currently $31.40.

Cetera Investment Advisers grew its stake in shares of Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) by 34.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,999 shares of the company's stock after buying an additional 10,756 shares during the period. Cetera Investment Advisers' holdings in Liquidia Technologies were worth $619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of LQDA. Bleakley Financial Group LLC boosted its stake in Liquidia Technologies by 6.4% during the first quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company's stock worth $373,000 after buying an additional 1,523 shares during the period. Significant Wealth Partners LLC raised its holdings in shares of Liquidia Technologies by 14.1% in the first quarter. Significant Wealth Partners LLC now owns 14,396 shares of the company's stock valued at $212,000 after acquiring an additional 1,780 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Liquidia Technologies by 2.9% in the first quarter. Bank of New York Mellon Corp now owns 194,131 shares of the company's stock worth $2,863,000 after purchasing an additional 5,547 shares in the last quarter. Valmark Advisers Inc. raised its holdings in Liquidia Technologies by 7.4% in the first quarter. Valmark Advisers Inc. now owns 18,641 shares of the company's stock worth $275,000 after purchasing an additional 1,283 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Liquidia Technologies in the first quarter worth about $911,000. Institutional investors own 64.54% of the company's stock.

Insider Buying and Selling

In other Liquidia Technologies news, CFO Michael Kaseta sold 30,000 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $20.00, for a total value of $600,000.00. Following the completion of the sale, the chief financial officer owned 376,412 shares of the company's stock, valued at $7,528,240. The trade was a 7.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jason Adair sold 2,576 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $36,785.28. Following the completion of the transaction, the insider directly owned 193,634 shares of the company's stock, valued at approximately $2,765,093.52. This trade represents a 1.31% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,277 shares of company stock valued at $1,469,392. 26.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LQDA has been the topic of a number of recent research reports. BTIG Research reiterated a "buy" rating on shares of Liquidia Technologies in a research report on Tuesday, May 27th. Wells Fargo & Company increased their price objective on Liquidia Technologies from $25.00 to $31.00 and gave the company an "overweight" rating in a research note on Wednesday. Raymond James Financial raised their target price on Liquidia Technologies from $33.00 to $41.00 and gave the stock a "strong-buy" rating in a research note on Wednesday. Bank of America lowered their target price on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a report on Wednesday, June 11th. Finally, HC Wainwright lifted their price objective on Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, May 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $31.40.

Liquidia Technologies Stock Performance

Shares of LQDA stock opened at $25.95 on Friday. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -15.26 and a beta of 0.14. Liquidia Technologies, Inc. has a 1-year low of $8.26 and a 1-year high of $26.65. The company has a current ratio of 2.49, a quick ratio of 2.91 and a debt-to-equity ratio of 9.84. The stock's fifty day simple moving average is $16.30 and its 200-day simple moving average is $15.52.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%. The company had revenue of $8.84 million during the quarter, compared to analyst estimates of $3.90 million. The firm's quarterly revenue was up 141.5% compared to the same quarter last year. On average, sell-side analysts predict that Liquidia Technologies, Inc. will post -1.51 earnings per share for the current fiscal year.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.